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ABSTRACT: In response to the side effects of antihypertensive drugs, dietary and lifestyle modification approaches have become 
alternative strategies for prevention and modulation of mild hypertension. Moreover, the use of low molecular size bioactive 
peptides (BAPs) as antihypertensive agents has gained particular attention as a result of the safety, low cost, and consumer 
preference for natural health products compared to drugs. BAPs are produced by enzymatic hydrolysis of food proteins followed 
by post-hydrolysis processing to fractionate the active peptides. Antihypertensive BAPs exert their effect mostly by modulating 
the renin-angiotensin system pathway leading to decrease in vasoactive peptides with concomitant reduction of elevated blood 
pressure associated with hypertension in animal models and humans. This review revisits the prevalence of hypertension and the 
molecular basis of activity, bioavailability and safety of BAPS as well as contradictions and controversies on the use of peptides as 
antihypertensive agents. 
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INTRODUCTION 
Hypertension is a controllable risk factor for developing 
cardiovascular disease and a major global public health concern. 
The prevalent treatment and management strategy against severe 
cases of hypertension involve the use of synthetic antihypertensive 
drugs, but the various side effects associated with therapeutic use 
of these drugs supports the need to discover alternative approaches 
to treatment and management of hypertension. The strategic use of 
food-derived natural compounds against molecular disease targets 
can provide safe and effective modulation of aberrant human health 
processes and diseases. Consequently, food protein-derived 
bioactive peptides (BAPs) have emerged as safer health-promoting 
agents that can be used to manage hypertension in humans. These 
peptides are liberated from native food proteins by specific and 
non-specific enzymatic proteolysis, and have shown tremendous 
prospects in modulating key physiological processes that lead to 
hypertension depending on their bioavailability in target tissues. 
This paper reviews the literature on the prevalence of hypertension 
in various populations as well as the molecular and clinical aspects 
of intervention against hypertension using BAPs, based mainly on 
modulation of the renin angiotensin system (RAS) pathway. 
Current research on the safety and bioavailability of BAPs in target 
cellular locations, and potential application as functional food 
ingredients for prevention and management of hypertension are 
also discussed. 
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DEFINITION AND CLASSIFICATION OF 
HYPERTENSION 
 Hypertension is currently defined by the presence of a 
sustained elevation of systemic arterial pressure above systolic 
(SBP) and diastolic blood pressure (DBP) ratio of 140/90 mmHg. It 
is usually induced by physiologic and/or psychologic stressors. 
Hypertension is a progressive cardiovascular syndrome that results 
from an array of distinct but interrelated etiologies.1 The sustained 
elevation of blood pressure (BP) is usually sequel to the presence of 
early markers of the disease. Hypertension is the most common 
non-communicable disease in the world.2 It is also the world’s 
leading cause of cardiovascular diseases.3 This is largely because 
the progression of hypertension is strongly associated with cardiac 
and vascular abnormalities that negatively affect the functions and 
structures of target organs like the heart, kidneys, brain, 
vasculature, etc, leading to premature and high levels of morbidity 
and mortality.1,4 
 The Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure, in its most 
recent report (JNC 7 report) classifies BP into four categories – 
normal, prehypertension, stage 1 hypertension and stage 2 
hypertension.5 Normal BP (<120/80 mmHg) is described as a case of 
blood pressure elevations and the absence of any identifiable 
cardiovascular disease. Prehypertension (120/80–139/89 mmHg) is 
characterized by occasional or intermittent blood pressure 
elevations and early cardiovascular disease. Stage 1 hypertension 
(140/90–159/99 mmHg) is defined as a case of sustained blood 
pressure elevations or progressive cardiovascular disease. It comes 
with overt early disease markers and early signs of target organ 
disease. This stage develops as a result of persistent structural and 
functional alterations in blood pressure control mechanisms. Stage 
2 hypertension (≥160/100 mmHg) is characterized by a marked and 
sustained blood pressure elevation or advanced cardiovascular 
disease. Cardiovascular disease risk factors, early disease markers 
and target organ disease are not only present, but are also 
progressive with or without cardiovascular disease events. The 
advanced stage of the hypertension continuum is exacerbated by 
aging, BP elevations and persistent disease risk factors.1,5 
EPIDEMIOLOGY 
Risk factors 
 Elevated BP is the single most important modifiable risk factor 
for hypertension. Randomized trials have established that reducing 
BP can prevent cardiovascular events, especially stroke.6,7 
Overweight and obesity are the next important modifiable risk 
factors for hypertension.8,9 The strongest risk factor for incident 
hypertension is overweight/obesity and both are independent and 
significant predictors of the level of blood pressure.10 In fact, 
according to the JNC report,5 a 10 kg weight loss promotes a 5 to 
20 mmHg reduction in blood pressure. A western-styled diet – 
high fat, high sugar, low fibre diet – is another modifiable risk 
factor for hypertension.  The Dietary Approaches to Stop 
Hypertension (DASH) trial illustrated for the first time that 
dietary intervention alone (using the DASH diet that is low in fat, 
low in sugar, and high in fibre among others) significantly lowers 
SBP and DBP by an average of 11.4 and 5.5 mmHg in hypertensive 
subjects and by 3.5 and 2.1 mmHg in non-hypertensive subjects, 
respectively.11 The above magnitude is comparable to that achieved 
by mono-pharmacotherapy for mild hypertension. Moreover, there 
is considerable scientific evidence linking high sodium intake 
(consumed as table salt) to hypertension and increased 
cardiovascular events,12 whereas a high intake of potassium, 
calcium and magnesium reportedly has a BP-lowering effect.10,11 
Furthermore, there is a direct dose-response relationship between 
alcohol consumption and hypertension. This is more so when 
alcohol consumption is in excess of 2 drinks per day.13 The 
reduction of alcohol consumption to less than 2 drinks a day can 
lower blood pressure by up to 4 mmHg.14 Physical inactivity is also 
a modifiable risk factor for hypertension. There is an established 
inverse relationship between physical activity level and blood 
pressure, and higher physical activity levels reduce the risk of 
hypertension by about 15%.15,16 
 The major non-modifiable risk factors for hypertension are age, 
gender and genetics. Hypertension and cardiovascular events occur 
more frequently during and after age 50 years. Hypertension is 
however thought to originate in childhood and adolescence and 
tracks into adulthood.17,18 The hypertension risk advantage that 
premenopausal women have, and lose after menopause is thought 
to be linked to hormones involved in renal salt handling.19 Sex 
differences in the frequency of hypertension is put at 4% in the 
United States, 8% in Canada and 11% in Western Europe.20 
However, from age 61 years onwards, the prevalence of 
hypertension becomes higher in women than in men.21 The 
prevalence of hypertension from a racial/ethnic point of view is 
highest among African Americans. Hypertension in blacks is more 
prevalent (though the incidence of hypertension has been shown to 
differ between blacks and whites only before age 74 years)22, and 
more severe, starts earlier in life, and has higher target organ 
morbidity.23 Blacks have higher peripheral vascular resistance, 
greater salt sensitivity and lower circulating levels of renin. About 
30% of all deaths among African Americans are attributable to 
hypertension.24 Conversion from prehypertension to hypertension 
is also accelerated in blacks25 Other identifiable causes of 
hypertension include sleep apnea, drug induced or related causes, 
chronic kidney disease, primary aldosteronism, renovascular 
disease, chronic steroid therapy and Cushing’s syndrome, 
pheochromocytoma, coarctation of the aorta, and thyroid or 
parathyroid disease.5 
Prevalence of hypertension 
 Kearney et al.3 reported that 26.4% of the adult population 
(26.6% of men and 26.1% of women) in 2000 had hypertension and 
29.2% (29.0% of men and 29.5% of women) were projected to have 
this condition by 2025, an increase to a total of 1.56 billion people. 
Accordingly, the total number of adults with hypertension in 2000 
was estimated at 972 million; 333 million in developed countries 
and 639 million in developing countries. The global hypertension 
prevalence is reportedly lowest in rural India (3.4% in men and 
6.8% in women) and highest in Poland (68.9% in men and 72.5% in 
women).2 In the United States, the prevalence of hypertension 
increased from 23.9% in the period 1988-1994, to 28.5% in the 
period 1999-2000, and to 29% in the period 2007-2008.26 A recent 
Udenigwe et al. Hypertension and food peptides Biokemistri 23(3):108-117 
110 
report put the figure for American adults with elevated blood 
pressure requiring treatment, at 150 million (32%).27 An analysis of 
data from the Canadian Heart Health Surveys (CHHS) reported a 
prevalence of 21.1% for Canadians aged 18-74 years.28 A very recent 
report29 shows that the prevalence of hypertension in Canada has 
been fairly stable (19.7% to 21.6%) between 1992 and 2009. The 
latter report shows that 21.6% of the adult population (25.5% of 
men and 17.8% of women) in 1992 had hypertension; 21.3% (23.8% 
of men and 19.0% of women) had the disease in 2006; while 19.7% 
(19.9% of men and 19.4% of women) had hypertension in 2009. 
 In sub-Saharan Africa, the prevalence of hypertension is higher 
in the urban areas compared to the rural areas. Hypertension is 
nevertheless age-dependent irrespective of place of domicile. A 
review by Addo et al.30 shows that the prevalence of hypertension 
(using the JNC 7 criteria) was lowest in rural Nigeria and Eritrea 
(14.5% each) and highest in urban Tanzania (39.1% for women and 
37.3% for men). The prevalence of hypertension in Nigeria has risen 
from 10% in 198731 to 17-20% in 199932 and 32.8% in 2010.33 The 
small sample size of the last mentioned study33 especially in the 
rural areas (n = 370), however, warrants a cautious comparison of 
the data to larger studies. There is yet (to our knowledge) no 
standardized nationally representative study of hypertension in 
Nigeria. In Ghana, the prevalence of hypertension has risen from 2-
5% in 197334 to 28.7% in 200335 and 25.4% in 2006.36 In a recent 
review of more than 70 published studies on hypertension in 
Ghana, it was reported that “most studies reported a crude 
prevalence of hypertension between 25% and 48% using the newer 
threshold of 140/90 mmHg” and “only four studies reported a 
prevalence of less than 20%”.37 Hypertension is without doubts, a 
very important global public health problem that cuts across 
ethnic and geographic differences, albeit to varying degrees. 
PHYSIOLOGICAL BLOOD PRESSURE REGULATION 
AND HYPERTENSION 
 As with other cellular processes, the human physiological 
processes possess strong regulatory mechanisms for controlling 
vascular tone and BP. The renin-angiotensin system (RAS) and the 
kinin-nitric oxide system (KNOS) are the major pathways for 
physiological BP regulation. As shown in Fig. 1, in the RAS 
pathway, angiotensinogen is hydrolyzed to release a decapeptide 
angiotensin (AT)-I by the cleavage of the C-terminal of Leu10 
located at the C-terminal region of the protein in the rate limiting 
step catalyzed by renin (E.C. 3.4.23.15; produced by renal cells). 
Mature renin is a 37 kDa 340 amino acid-residue enzyme that 
belongs to the aspartate protease family, uniquely characterized by 
the presence of two Asp residues in their active sites. In the second 
step of RAS, AT-I is converted to a potent octapeptide 
vasoconstrictor, AT-II, by cleavage of His-Leu from C-terminal by 
zinc metallopeptidase, angiotensin I-converting enzyme (ACE; 
E.C. 3.4.15.1), which is produced predominantly in the lungs.38 
Subsequently, AT-II binds its receptors to trigger a physiological 
cascade that induces vasoconstriction, aldosterone secretion, salt 
reabsorption and water retention.38 On the other hand, the KNOS 
pathway plays a role in the regulation of bradykinin (a 
vasodilator), which elicits physiological processes that lead to 
increased intracellular Ca2+ that forms a complex with calmodulin 
to activate endothelial nitric oxide synthase (NOS), which 
catalyzes the synthesis of nitric oxide (NO) from L-arginine; NO is 
responsible for the vasoregulatory effect of bradykinin.38,39 In 
addition to AT-II synthesis, ACE also catalyzes the hydrolysis of 
bradykinin into inactive fragments leading to additional effects in 
BP elevation (Fig. 1). Excessive enzymatic activity due to over-
expression of ACE can lead to elevation of BP followed by 
hypertension. Thus, the modulation of physiological ACE activity 
has since been exploited towards the discovery of antihypertensive 
agents (e.g. captopril) because its inhibition in hypertensive 
subjects will lead to decreased AT-II and elevated bradykinin 
concentrations with concomitant decrease in BP. Moreover, the 
inhibition of ACE activity does not guarantee effective reduction of 
elevated BP during hypertension because formation of vasoactive 
AT-II can also occur in some tissues via ACE-independent 
pathway catalyzed by chymase, tonin or cathepsin.38,40,41 
Consequently, the inhibition of renin activity with drugs (e.g. 
aliskiren) has been developed as a more effective and selective 
approach towards treatment and management of hypertension.41 
MODULATION OF THE RENIN-ANGIOTENSIN 
SYSTEM BY BIOACTIVE PEPTIDES (BAPS) 
BAPs-induced ACE inhibition 
 The activity of ACE has been widely targeted for 
antihypertensive therapy. The use of peptides as ACE inhibitors 
was first reported for insect venom peptides 42,43 and these reports 
were followed by numerous studies that discovered ACE-
inhibiting peptides from an enormous list of proteins from plant, 
animal and marine sources (see review articles by Hartman & 
Meisel44 and Udenigwe & Aluko45). Fig. 2 shows a schematic 
representation of the processes involved in the production and 
characterization of BAPs from food proteins and evaluation of their 
relevant biological properties. Of particular interest to several 
FIGURE 1 The renin-angiotensin system (RAS) and kinin-nitric 
oxide system (KNOS) pathways for BP regulation showing 
molecular targets for antihypertensive BAPs 
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FIGURE 2 The process of production and processing of BAPs, and evaluation of antihypertensive effects using different models 
research groups are the milk-derived tripeptides or 
lactotripeptides (LTPs), IPP and VPP, derived from β-casein (f74-
76 and f84-86, respectively), which have been widely evaluated for 
antihypertensive properties due to their potent ACE-inhibitory 
activities (IC50 of 5 and 9 µM, respectively).
46 The LTPs were 
liberated from β-casein during fermentation with Lactobacillus 
helveticus and Saccharomyces cerevisiae.46 Other ACE inhibiting BAPs 
have been derived from fish and egg proteins but the abundance of 
plant proteins provides an advantage over animal proteins as 
sources of BAPs. In addition to purified peptides, crude enzymatic 
protein hydrolysates have also shown ACE-inhibitory properties, 
and their use as antihypertensive agents is encouraged to reduce 
cost and labour-intensive peptide purification steps. However, the 
use of peptide mixtures in modulating ACE activity might not lead 
to potent activity due to the possible low abundance of the active 
principles within the mixture. Marine-derived proteins have 
shown excellent potential due to the large amount of processing 
by-products, and these underutilized products are now exploited 
as sources of ACE inhibiting BAPs.47 For example, Alcalase-
catalyzed hydrolysis of Atlantic salmon collagen followed by RP-
HPLC purification resulted in the isolation of dipeptides (AP and 
VR), which inhibited ACE activity with IC50 of 0.06 and 0.33 
mg/ml representing 20- and 4-fold enhancement, respectively 
compared to the activity of the crude hydrolysates48; this 
highlights the need for extensive purification for increased potency 
of BAPs. 
 A comprehensive library of food protein-derived ACE-
inhibiting peptides can be found in BIOPEP database 
(http://www.uwm.edu.pl/biochemia/index.php/en/biopep). In fact, 
a bioinformatic-based approach using the BIOPEP program can be 
used for production of potent ACE inhibitors by in silico hydrolysis 
of primary sequence of the proteins for optimization of the 
enzymatic process. This approach showed excellent potential in 
identifying appropriate proteolytic enzymes and food protein raw 
materials, based on preponderance of active peptide sequences 
within the primary structure of the protein49; however, the use of 
this approach is limited to proteins with known primary sequence, 
and sound knowledge about the structure-function properties of 
peptides is often required. Since most points in evidence on the 
ACE-inhibitory activities of BAPs are based on in vitro evaluations, 
there are concerns as to whether the observed interactions 
between ACE and BAPs can be replicated in vivo especially for 
unstable and poorly absorbed BAPs. 
BAPs-induced renin inhibition 
 Recent studies have shown evidence that some food protein-
derived BAPs possess the ability to inhibit renin activity. The 
initial study demonstrated that low molecular size peptides 
derived from enzymatic hydrolysis of flaxseed proteins exhibited 
low to moderate renin-inhibitory activities via mixed-type 
inhibition pattern, possibly due to multiple interactions of renin 
with various components of the peptide mixtures.50 The fact that 
these BAPs showed multifunctional property by inhibiting both 
renin and ACE activities suggests possible in vivo potency as 
antihypertensive agents. Similar studies have also reported the 
release of renin inhibitors (IC50 0.81 mg/ml) by simulated 
gastrointestinal digestion of hempseed proteins with pepsin and 
pancreatin51, which indicates that beneficial BP-reducing effects 
can potentially result from consumption of native hempseed 
proteins depending on bioavailability of the resulting BAPs. 
Furthermore, a number of dipeptides have been identified from a 
pea protein hydrolysate fraction as renin inhibitors45,52, including 
dipeptides IR, KF and EF with IC50 values of 9.2, 17.8 and 22.6 mM, 
respectively.52 The wide range of activities observed for these 
peptides and their distinct structural properties provided a 
platform for the study of their structure-function relationships, 
and it is expected that such studies will provide fundamental 
knowledge of inhibitory mechanisms and peptide templates for the 
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design of peptidomimetics with enhanced potency and 
bioavailability. 
Structural requirements of BAPs for inhibition of RAS enzymes 
 The mechanism of ACE inhibition by BAPs has been studied 
using both synthetic and natural peptides. Most ACE-inhibiting 
BAPs exert their activities by competitive inhibition but some 
peptides have also exhibited non-competitive (e.g. LW and IY) and 
uncompetitive (e.g. IW and FY) inhibition.53,54 Structural 
properties such as chain length, steric properties, net charge and 
hydrophobicity constitute important factors that determine 
potency of BAPs in inhibiting ACE.55 Consequently, detailed 
knowledge of the structure-activity relationship of BAPs can 
enhance the discovery of more potent BAPs. It was earlier proposed 
that ACE inhibition by BAPs involves three circular hydrophobic 
clefts located at ACE catalytic site, which were designated as the 
major sites for interaction of C-terminal residues of BAPs.56 This 
implies that BAPs containing hydrophobic amino acid residues 
could effectively bind these hydrophobic pockets, depending on 
structural conformation, where they are held together by 
hydrophobic interaction. As a result, it was observed that most 
competitive ACE-inhibiting BAPs contain hydrophobic amino acid 
residues in their sequence.53,56  
 Quantitative structure-activity relationship (QSAR) studies 
have been conducted in attempt to elucidate the structure-
function properties of BAPs. The prevalent method utilizes a 
chemometric approach – the partial least squares projection of 
latent structure (PLS) – to design models that relate bioactivity 
data to the physicochemical properties of BAPs. Using the z-scale 
amino acid descriptors (z1, hydrophobicity; z2, molecular 
size/steric effects; z3, electronic properties), a library of BAPs was 
used to develop PLS models that showed that, for di- and 
tripeptides to exhibit potent ACE inhibition, the C-terminal amino 
acid residues must be hydrophobic and bulky (e.g. Phe, Trp, Pro, 
Tyr) whereas the N-terminal amino acid residues should preferably 
be aliphatic (e.g. Ile, Leu, Val).57 Typical examples of BAPs with 
such structural features include potent antihypertensive LTPs, 
which possess N-terminal Ile or Val and C-terminal Pro residues. 
Moreover, for oligopeptides with four or more (up to 10) amino 
acid residues, other QSAR PLS models demonstrated that the last 
four amino acid residues at the C-terminal of the peptides should 
be hydrophobic for potency and that these residues play major 
roles in determining the ACE–inhibitory activities of these 
peptides.58 These findings indicate that the ACE-inhibiting BAPs 
with strong hydrophobicity act possibly by interacting with the 
hydrophobic pockets of the catalytic site of the enzyme. Using 
short peptide fragments derived from ACE-inhibiting decapeptide 
(VTVNPYKWLP), the presence of Trp (W) in BAPs has been 
demonstrated to promote ACE inhibition59 possibly based on 
hydrophobicity and steric effects. 
 Although there is a strong positive correlation between 
hydrophobicity and bitterness of BAPs, a limiting factor in 
nutraceutical application of BAPs, there was no significant 
statistical relationship between bitterness property and ability of 
di- and tripeptides to inhibit ACE60; therefore, the low-molecular 
size peptides can potentially be incorporated into health-
promoting functional foods with little concern about negative 
sensory quality. As with ACE inhibition, a recent QSAR study 
reported similar structural requirements for dipeptide inhibitors of 
renin although there is no similarity in the primary and 3-
dimensional structures of ACE and renin, and no correlation was 
observed between the activities of the peptides in inhibiting the 
two RAS enzymes.45 In fact, similarity in structural requirements 
increases the feasibility of using a single peptide (e.g. IW) to 
modulate the activities of both ACE and renin leading to more 
pronounced reduction in BP compared to peptides that inhibit the 
activity of only ACE or renin.45,53 
ANIMAL STUDIES WITH ANTIHYPERTENSIVE BAPS 
 Spontaneously hypertensive rats (SHR) have been widely used 
as animal model of essential hypertension for studying the BP-
lowering effects of BAPs. The LTPs (IPP/VPP) independently 
lowered elevated SBP by maximum values of 28.3 and 32.1 mmHg, 
respectively, in SHR; several other bovine casein-derived peptides 
with 2−12 amino acids in their sequence induced ΔSBP ranging 
from −2 to −34 mmHg with the maximum activity displayed by αS1-
casein-derived FFVAPFPEVFGK (f23−34).61 These effects on BP 
were attributed to ACE inhibition by the BAPs; moreover, calcium 
present in fermented milk products has been suggested to promote 
BP-lowering effect of the BAPs product in SHR.62 Apart from the 
lactopeptides, a pea protein-derived peptide product demonstrated 
both short-term BP reduction in SHR following oral gavage (ΔSBP, 
−19 mmHg after 4 h) and long-term effects in hypertensive chronic 
kidney disease (Han:SPRD-cy) rats (SBP, −29 mmHg; DBP, −25 
mmHg after 8 wks) although the peptides were poorly active 
during in vitro evaluation.63 In the Han:SPRD-cy rats, the pea 
peptide product induced reduction of renal renin mRNA 
expression and plasma AT-II level but showed no effect on renal 
expression of ACE or plasma ACE activity.63 This pattern of 
activity indicates that the pea-derived BAPs modulated renin, not 
ACE, thereby reducing the amount of AT-II with concomitant 
lowering of elevated BP in the hypertensive rats. Moreover, other 
studies have reported substantial BP-lowering effects of crude 
enzymatic hydrolysates of hempseed51, apricot almonds64, soy, 
wheat gliadin, casein, and whey65 after short-term oral gavage of 
the products to SHR (Table 1). Despite the potent antihypertensive 
activities of the food-derived BAPs in animals, these data cannot be 
directly applied to hypertensive humans due to complexity of the 
human physiology; thus, BP-lowering potential of BAPs needs to be 
evaluated in hypertensive humans prior to health claims and 
commercialization of the products. 
TABLE 1 Short-term maximum systolic blood pressure (SBP)-lowering 
activity of BAPs-containing enzymatic protein hydrolysates in 









Hempseed 200 –30.0 Girgih et al.51 
Corn  100 –26.5 Huang et al.66 
Pea 200 –19.0 Li et al.63 
Apricot almond 400, 800 –17.2, –20.8 Wang et al.64 
Soybean 100 –30.0 Ibe et al.67 
Porcine  10 –23.0 Muguruma et al.68 
Tuna frame 10 –21.0 Lee et al.69 
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TABLE 2 Summary of meta-analyses of placebo-controlled clinical trials conducted with food protein hydrolysates and 
peptides in human subjects with different stages of hypertension 
 
HUMAN CLINICAL TRIALS WITH ANTI-
HYPERTENSIVE BAPS 
 Physiological BAPs-induced inhibition of ACE and renin 
activities during hypertension will ultimately result in decrease in 
the amount of circulating AT-II, and increased amount of 
bradykinin; and these would consequently lead to decrease in 
elevated BP. Several human clinical trials have shown evidence that 
BAPs in fermented milk possess antihypertensive effects in human 
subjects with mild hypertension.70-72 A recent study reported that 
consumption of milk protein hydrolysates enriched with the LTPs, 
IPP/VPP, induced −3.8 and −2.3 mmHg change in SBP and DBP, 
respectively, in prehypertensive and stage 1 hypertensive subjects 
using office BP measurements.73 Moreover, no significant decrease 
in BP was observed in the study in prehypertensive subjects 
compared to placebo indicating that substantial BP elevation is 
prerequisite for the antihypertensive effects of the peptides. 
Moreover, LTPs-based peptide product (AmealPeptide) was found 
to induce decrease in daytime ambulatory SBP (−3.6 mmHg) and 
mean 24-h SBP (−2 mmHg) in treated and newly diagnosed 
(treatment-naive) stage 1 and stage 2 hypertensive subjects that 
consumed a 150-mg dose of the product daily for 6 wks; more 
pronounced effects on daytime SBP was observed for treatment-
naive subjects compared to placebo.74 Apart from milk-derived 
peptides, plant protein-derived BAPs have also shown prospects 
for management of human hypertension. In hypertensive humans, a 
pea protein-derived peptide product was recently reported to have 
reduced SBP by 6 mmHg after 3 wks of treatment with 1.5 g/day of 
the peptides consumed with orange juice as delivery vehicle.63 
Although studies have demonstrated correlation between BAPs-
induced BP reduction and decreased activity of plasma RAS 
enzymes or amounts of vasoactive peptides75, there is evidence that 
the antihypertensive activity of certain BAPs occurred without 
changes in renin activity, AT-I or AT-II levels.73 Thus, there may be 
alternative routes for BP lowering by BAPs other than RAS 
modulation. For example, amaranth protein-derived BAPs with in 
vitro ACE-inhibitory activity was found to induce activation of 
endothelial NOS by phosphorylation at the Ser117 residue leading 
to smooth muscle relaxation in isolated rat aortic segments76; the 
observed effect was due to the synthesis of vasodilator, NO, that 
mediates lowering of BP during hypertension. 
 In contrast, some studies have reported lack of substantial 
BAPs-induced decrease in elevated BP. In a multicentre crossover 
study with untreated hypertensive white subjects (n=162), Van 
Mierlo and co-workers77 reported that LTPs (IPP/VPP) 
administered in form of dairy drink did not significantly affect 
mean 24-h ambulatory BP compared to placebo. Likewise, 
administration of LTPs-containing fermented milk or placebo to 94 
prehypertensive and borderline hypertensive subjects daily for 8 
wks did not result in any significant difference in SBP and DBP 
between the groups.78 Actually, the latter study observed that the 
slight change in BP due to the LTPs was not better than BP 
decreases that result from lifestyle intervention for lowering BP, 
which raises concerns with respect to balance between cost and 
efficacy/benefits of the BAPs. The contrasting findings on BP-
lowering effects of BAPs can be attributed to a number of factors 
including genetic, dietary and lifestyle variations in the different 
populations, study design, vehicle of delivery of the peptides and 
mode of BP measurement. Therefore, there is need to develop 
standardized protocols for clinical intervention trials with BAPs 
and precise tools for BP measurements (e.g. ambulatory BP 
measurement) for comparison of data conducted in various 
locations. To the best of our knowledge, there is dearth of 
literature information on studies that evaluated the potential use of 
food-derived BAPs for the management of hypertension in an 
African population; this approach towards the reduction of 
elevated BP is encouraged considering the abundance of potential 
raw materials on the African continent for the production of BAPs. 
META-ANALYSES OF CLINICAL TRIALS 
 Due to conflicting results from human intervention studies 
with food-derived peptides, meta-analyses of several placebo-
controlled trials have been conducted to confirm the presence or 
absence of BP-lowering effects by the peptides. As shown in Table 
2, meta-analyses of human clinical trials showed that food protein 
hydrolysates and peptides have the ability to reduce both SBP and 
DBP in subjects with different stages of hypertension. As much as 
−5.13 and −2.4 mmHg change in SBP and DBP, respectively were 





Outcome (mmHg)  
References ΔSBP ΔDBP 
LTPs (VPP and IPP) Eighteen clinical trials (28 groups, n=885) with 
untreated subjects with hypertension 
−3.73 −1.97 Cicero et al.79 
LTPs (VPP and IPP) Twelve clinical trials (n=623) with pre-hypertensive 
and hypertensive subjects 
−4.80 −2.20 Xu et al.80 
Peptides and protein 
hydrolysates derived 
from milk and fish 
(mostly LTPs) 
Fifteen clinical trials (17 groups, n=423) with subjects 
with normal high BP and mild hypertension 
 
−5.13 −2.40 Pripp81 
LTPs (IPP/VPP) Five randomized clinical trials in mild hypertensive 
and hypertensive subjects (n=295) 
−4.00 −2.10 Jauhianen et al.82 
SBP, systolic blood pressure; DBP, diastolic blood pressure; LTPs, lactotripeptides 
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hypertension after receiving various enzymatic protein 
hydrolysates and peptides derived from milk (LTPs) and fish.81 
These values are encouraging since −5 and −2.5 mmHg change in 
SBP and DBP, respectively can reduce the risk of coronary artery 
disease and stroke by 12% and 20%, respectively, irrespective of the 
mode of intervention.7 Moreover, it was demonstrated that the 
LTPs showed more pronounced reduction of BP in hypertensive 
subjects compared to those with mild cases of hypertension.80 This 
observation indicates that the BAPs may have modulated the 
increased levels of BP-regulating molecules with little or no effect 
on their basal levels. In addition, Cicero and co-workers79 reported 
based on meta-analysis that efficacy of the LTPs in lowering ele-
vated blood pressure is dependent on ethnic factors, since Asian 
subjects (ΔSBP, −6.93 mmHg; ΔDBP, −3.98 mmHg) were found to 
be more responsive to the BAPs-based intervention than Caucasian 
subjects (ΔSBP, −1.17 mmHg; ΔDBP, −0.52 mmHg). This discrep-
ancy could be attributed to genetic variation or different dietary 
lifestyles of the populations; however, there is need to conduct 
appropriate studies to explain these responses. Furthermore, 
LTPs-induced BP-lowering effects in human subjects were 
observed to be independent of baseline BP, treatment duration, 
peptide dose and age of subjects.79 BAPs-based interventions in 
some populations clearly show prospects for the control of 
hypertension and associated vascular disease since the slight BP 
reduction induced by the potent peptides can be combined with 
lifestyle modification practices to potentially produce substantial 
reduction in elevated BP during hypertension. 
BIOAVAILABILITY AND SAFETY OF FOOD-DERIVED 
ANTIHYPERTENSIVE PEPTIDES 
 Oral consumption of BAPs increases their susceptibility to 
degradation into inactive fragments by gastrointestinal, brush 
border and serum peptidases. Therefore, antihypertensive BAPs 
must withstand proteolytic inactivation and be absorbed through 
the enterocytes into circulation in order to exert their BP-lowering 
effects during hypertension. There is considerable evidence that 
antihypertensive di- and tripeptides are absorbed intact in 
humans83-85 since their transepithelial movement can be facilitated 
by peptide transporters (PepT) that are expressed in enterocytes; 
small oligopeptides can sometimes escape peptidolysis and cross 
the enterocytes through hydrophobic regions of intestinal 
membrane epithelia or tight junctions.86 After consumption of 
yogurt containing the antihypertensive LTP by normotensive 
subjects, IPP was detected in nanomolar concentrations in the 
plasma of subjects indicating efficient absorption and 
bioavailability.83 In addition to chain length, other factors that 
influence bioavailability include charge, lipophilicity and solubility 
of BAPs.86 
 Based on the literature, food protein-derived BAPs are 
considered safe for human consumption since studies in animals 
and human subjects demonstrated lack of adverse effects of the 
peptides compared to placebo. For example, Anadon and co-
workers demonstrated that a single dose of 2000 mg/kg BW and 
repeated daily doses of 1000 mg/kg BW (higher than typical 
therapeutic doses) of antihypertensive lactopeptide (αs1-casein 
f90–94 and f143–149)-containing hydolysates had no negative 
effects on clinical parameters and mortality in rats.87 Moreover, 
LTP-rich products were reported to have no significant adverse 
effects on serum and urine chemistry in prehypertensive and 
hypertensive human subjects compared to placebo.73,74 It appears 
that BAPs also showed no adverse effect in normotensive 
subjects.85 These points in evidence indicate that food protein-
derived antihypertensive BAPs are safer for human consumption 
compared to synthetic antihypertensive drugs. 
COMMERCIAL BAPS-BASED ANTIHYPERTENSIVE 
PRODUCTS 
 A number of BAPs-based food products with antihypertensive 
properties have been commercialized and marketed by 
international food companies. Table 3 shows a list of some of these 
products, their food sources and, in some products, the sequence of 
the active peptides. Most of the peptide products are derived from 
milk proteins; Calpis AMEEL and Evolus are formulated with LTPs 
(IPP/VPP) whereas BioZate and Peptide Soup are composed of a 
mixture of peptides.44 These BAPs products have demonstrated a 
wide range of BP-lowering activity in hypertensive human subjects 
in certain populations with ΔSBP of −4.5 to −14.9 mmHg and ΔDBP 
of −3.6 to −8.8 mmHg.61 
TABLE 3 Commercial antihypertensive peptide productsa 
CONCLUSION 
 Based on available evidence, there are prospects in the use of 
food-derived BAPs and protein hydrolysates for the management of 
hypertension in some human populations although contradictory 
evidence indicates otherwise in other populations. The mild BP-
reductions observed for these peptide products are generally lower 
than the activity of antihypertensive drugs but the natural form of 
food protein-derived BAPs can promote their use as safe 
antihypertensive agents. Moreover, future studies are needed to 
elucidate the long-term systemic molecular interactions of 
antihypertensive BAPs with the human genome, proteome and 
other cellular processes to ensure absolute safety, and possibly to 
explain the observed variation in potency of the peptides in 
different populations. It would also be economically beneficial to 
discover approaches that will yield high amounts of crude protein 
hydrolysates with potent BP-lowering effects to obviate the need 
for extensive peptide purification, which may alter the natural 
integrity and safety of BAPs. Finally, the economic and health-
Product Food 
source 
Active peptide Manufacturer 
Calpis AMEEL S Sour milk VPP/IPP Calpis Co., Japan 
Evolus Fermented 
milk 
VPP/IPP Valio, Finland 
BioZate Whey Peptide mixture Davisco, USA 




Peptide Soup Bonito Peptide mixture NIPPON, Japan 
Casein DP 
Peptio Drink 
Ingredient Casein-derived  
FFVAPFPEVFGK 
Kanebo, Japan 
a Derived from Hartman & Meisel44 
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promoting values of protein-rich foods and food processing by-
products in African countries can be potentially increased by using 
these products as raw materials for the production of 
antihypertensive BAPs. 
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